Oscar Briseno, MD
Cardiovascular Disease · Mount Vernon, WANPI 1770794331
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Abbott at 52.8% of the total. 2024 is the largest year on record at $155, 2.3 times the $69 reported in 2021. That places this record below the midpoint for cardiovascular disease clinicians in WA, where the typical reported total is $606.
Across 13 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$187
- Boston Scientific$71
- Kestra Medical Technology Services, Inc.$63
- Medtronic$18
- Terumo Medical Corporation$15
What the payments were for
- Food & beverage$354100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $187 |
| Boston Scientific | 1 | $71 |
| Kestra Medical Technology Services, Inc. | 2 | $63 |
| Medtronic | 1 | $18 |
| Terumo Medical Corporation | 1 | $15 |
How this compares
$354 in reported general payments places this provider in the 35th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 466 | $606,514 |
| XareltoRivaroxaban | 243 | $301,743 |
| EntrestoSacubitril/Valsartan | 176 | $253,442 |
| JardianceEmpagliflozin | 74 | $88,287 |
| Repatha SureclickEvolocumab | 74 | $87,409 |
| Metoprolol Succinate | 828 | $15,864 |
| PradaxaDabigatran Etexilate Mesylate | 47 | $13,939 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 37 | $13,797 |
| Atorvastatin Calcium | 692 | $8,137 |
| Flecainide Acetate | 89 | $6,085 |
| Losartan Potassium | 516 | $5,929 |
| Carvedilol | 483 | $5,126 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 118 | $4,158 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 206 | $4,158 |
| Spironolactone | 413 | $4,146 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Mount Vernon
- Bhrigu ParmarMount Vernon$21K
- Robert BersinBellevue$657K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Munish Kumar KannabhiranRichland$85K
- Erik WissnerSeattle$67K
- Younghoon KwonSeattle$66K
- Thomas AmidonBellevue$64K
- Aron BenderSeattle$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.